Pharmacological treatment and current controversies in COPD

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzola, Mario, Rogliani, Paola, Stolz, Daiana, Matera, Maria Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719668/
https://www.ncbi.nlm.nih.gov/pubmed/31508197
http://dx.doi.org/10.12688/f1000research.19811.1
_version_ 1783447973538037760
author Cazzola, Mario
Rogliani, Paola
Stolz, Daiana
Matera, Maria Gabriella
author_facet Cazzola, Mario
Rogliani, Paola
Stolz, Daiana
Matera, Maria Gabriella
author_sort Cazzola, Mario
collection PubMed
description Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.
format Online
Article
Text
id pubmed-6719668
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-67196682019-09-09 Pharmacological treatment and current controversies in COPD Cazzola, Mario Rogliani, Paola Stolz, Daiana Matera, Maria Gabriella F1000Res Review Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies. F1000 Research Limited 2019-08-29 /pmc/articles/PMC6719668/ /pubmed/31508197 http://dx.doi.org/10.12688/f1000research.19811.1 Text en Copyright: © 2019 Cazzola M et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Cazzola, Mario
Rogliani, Paola
Stolz, Daiana
Matera, Maria Gabriella
Pharmacological treatment and current controversies in COPD
title Pharmacological treatment and current controversies in COPD
title_full Pharmacological treatment and current controversies in COPD
title_fullStr Pharmacological treatment and current controversies in COPD
title_full_unstemmed Pharmacological treatment and current controversies in COPD
title_short Pharmacological treatment and current controversies in COPD
title_sort pharmacological treatment and current controversies in copd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719668/
https://www.ncbi.nlm.nih.gov/pubmed/31508197
http://dx.doi.org/10.12688/f1000research.19811.1
work_keys_str_mv AT cazzolamario pharmacologicaltreatmentandcurrentcontroversiesincopd
AT roglianipaola pharmacologicaltreatmentandcurrentcontroversiesincopd
AT stolzdaiana pharmacologicaltreatmentandcurrentcontroversiesincopd
AT materamariagabriella pharmacologicaltreatmentandcurrentcontroversiesincopd

Ejemplares similares